суббота, 24 сентября 2016 г.

FDA approves lower-cost alternative to biotech drug Humira

FDA approves lower-cost alternative to biotech drug Humira


Federal regulators on Friday approved the first alternative version of the second-best selling drug in the world, Humira, the blockbuster injection used to treat rheumatoid arthritis and other inflammatory diseases. The Food and Drug Administration cleared a near-copy of the drug, dubbed Amjevita, developed by Amgen Inc. Regulators approved the drug for more than a half-dozen conditions listed on the original drug's label, including severe psoriasis and Crohn's diseases.



from Biotech News